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Objective. To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed
Wegener’s granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease.
Methods. We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study
Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary
artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict
the absolute risk of a CV event. The model was tested using the Wegener’s Granulomatosis Etanercept Trial (WGET)
cohort.
Results. Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33
(11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds
ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11–1.90), diastolic hypertension (OR 1.97, 95% CI 0.98–3.95), and
positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20–0.74). The model
was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80).
Conclusion. Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and
validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients
without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to
myeloperoxidase ANCA or negative ANCA status.
INTRODUCTION
Wegener’s granulomatosis (WG) and microscopic polyan-
giitis (MPA) are the 2 most common types of small- and
medium-vessel vasculitis, with an estimated combined
prevalence of 49–254 per million in Europe and North
America (1). Untreated these diseases are fatal, but modern
therapy has dramatically improved survival (2–8). How-
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ever, patients continue to experience long-term morbidity
and mortality from persistent low-grade activity and per-
manent damage caused by the acute phase of vasculitis or
its treatment (9). An important component of this in-
creased long-term morbidity and mortality is from cardio-
vascular (CV) disease, which was highlighted in a retro-
spective review of the Danish National Hospital Register,
where patients with WG showed an increased rate of a
myocardial infarction (MI) within the first 5 years after a
diagnosis of WG compared to the general population (haz-
ard ratio 3.6) (10). In addition, a retrospective study
showed that patients with WG and MPA, when matched
for renal function and other traditional risk factors, had
double the rate of CV events (11). Theories for the in-
creased CV events in vasculitis include systemic inflam-
mation and endothelial dysfunction (12,13), factors asso-
ciated with increased CV risk in other inflammatory
diseases (14–16).
In 1995, the European Vasculitis Study Group (EUVAS)
launched randomized controlled trials for the treatment of
WG and MPA with unified trial protocols and data collec-
tion procedures; 4 of these trials have been published
(4,6–8,17). Patient enrollment in the 4 trials was stratified
by the degree of renal involvement. Subsequent to the
completion of these trials, EUVAS has performed a long-
term followup study on patients enrolled in these original
trials. Together, this cohort represents the largest ever
prospectively studied group of patients with WG and
MPA.
The aims of this study were to 1) review the CV events in
the first 5 years from the long-term followup of the 4
EUVAS trials, 2) use these data to create a prognostic tool
aimed at predicting the 5-year risk of CV events in patients
with newly diagnosed WG and MPA who have no CV
disease at diagnosis, and 3) validate the tool in a second
separate cohort of vasculitis patients.
PATIENTS AND METHODS
The patients and methods of the first 4 EUVAS random-
ized controlled trials included in the long-term followup
study have previously been described (4,6–8,17). In sum-
mary, all of the patients had a new diagnosis of WG, MPA,
or renal-limited vasculitis. Patients were stratified into the
4 studies by the severity of renal involvement, listed here
in order: 1) MEPEX: comparison of plasma exchange to
methyl prednisone in patients with severe renal disease
(creatinine level 500 mmoles/liter or requiring dialysis)
(7), 2) CYCAZAREM: maintenance therapy with azathio-
prine versus cyclophosphamide in patients with a renal
manifestation (creatinine level 500 mmoles/liter) or with
generalized life-threatening disease (4), 3) CYCLOPS: in-
duction therapy comparing daily oral cyclophosphamide
with pulsed intravenous cyclophosphamide in patients
with generalized disease (creatinine level 500 mmoles/
liter) (8), and 4) NORAM: a comparison of methotrexate to
cyclophosphamide for induction treatment in patients
with a creatinine level 150 mmoles/liter and without
critical organ-threatening disease (6). The study methods,
data collection procedures, and disease scoring were con-
sistent between the 4 trials.
For the validation set, we used anonymized data from
patients enrolled in the Wegener’s Granulomatosis Etaner-
cept Trial (WGET), i.e., 180 patients with active WG who
were randomized to receive etanercept or placebo in ad-
dition to standard maintenance therapy (18). Long-term
followup of this cohort is now available, including CV
events. Data from 136 patients without preexisting CV
disease were available for testing our regression model.
Sixteen of 136 patients in the WGET cohort had a CV
event: 14 with a nonfatal cardiac event (MI, coronary ar-
tery bypass graft, or percutaneous coronary intervention),
1 nonfatal stroke, and 1 CV death. Baseline demographics
for the EUVAS and WGET cohorts are shown in Table 1.
Ethics approval was obtained for each participating site
as per local requirements. A questionnaire on vital status
and CV events was completed on all eligible patients by
clinical investigators at each participating site. Informa-
tion was collected at 5 years from entry into the original
study, and also at the last available followup. The data-
bases containing baseline information for the 4 trials were
merged with the long-term followup results. All patients
with an entry diagnosis of renal-limited vasculitis were
considered to have MPA for this analysis.
The primary outcome measure of interest in this sub-
analysis was a CV event within 5 years after enrollment
into the original EUVAS trial. We defined a CV event as
death from any CV cause, nonfatal stroke, nonfatal MI, and
coronary artery bypass graft or percutaneous coronary in-
tervention. The identification of CV death was based on
the local investigator reporting death and cause of death.
The cause of death was adjudicated by an independent
panel. The observed CV death rate in the EUVAS trials was
compared to the predicted CV death rate (adjusted for age
and country of origin). The relevant European and Mexi-
can CV death rates for the year 2002 based on the World
Health Organization Statistical Information System data-
base (online at http://www.who.int/whosis/en/) are pro-
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vided in Supplementary Appendix A (available in the
online version of this article at http://onlinelibrary.wiley.
com/journal/10.1002/(ISSN)2151-4658).
Determination of nonfatal MI required evidence of elec-
trocardiogram changes or cardiac enzyme elevation. Non-
fatal stroke was defined as a focal neurologic deficit
present for at least 3 months (i.e., transient ischemic
events were not included). All items recorded at baseline
from entry into each trial such as patient demographics,
clinical features, blood results, disease activity scores (Bir-
mingham Vasculitis Activity Score [BVAS], versions 1 and
2]) (19), and disease damage scores (Vasculitis Damage
Index) (20), including individual components of these in-
struments, were available as predictor variables. Hyperten-
sion in the development cohort (EUVAS trials) was de-
fined as a diastolic blood pressure 95 mm Hg at the time
of entry into the trial that was attributable to active vasc-
ulitis (irrespective of whether the patient had a previous
history of hypertension or was receiving antihypertensive
treatment). This definition of hypertension was chosen
because of how the data were captured in the original trials
(based on a BVAS item). For the validation sample (WGET
cohort), hypertension was defined as a diastolic blood
pressure 95 mm Hg at trial entry, irrespective of previous
history of hypertension or antihypertensive therapy. Attri-
bution of the diastolic hypertension to vasculitis in the
WGET cohort was not included in the definition because it
was not captured in the original trial.
A points-based Cox Framingham CV risk prediction tool
(21) that uses body mass index (BMI) instead of total and
high-density lipoprotein cholesterol was used to test how
well a general population risk model performed in patients
with vasculitis. We simplified systolic blood pressure to
140 mm Hg (0 points on the scoring system) versus 140
mm Hg (3 points for women, 2 points for men) because of
the way in which hypertension was recorded in the data
set.
We used 2 methods to validate our new regression mod-
el: 1) bootstrapping, an internal validation technique used
to obtain a bias-corrected estimate in the development
sample (22), and 2) testing the model in the validation
cohort using receiver operator characteristics.
Data were analyzed using the statistical software pack-
age Stata, release 10.1. Univariate logistic regression mod-
eling was used to examine the association between base-
line variables and CV events. Fractional polynomial
regression modeling was used to model nonlinear relation-
ships for continuous variables. A multivariate logistic re-
gression model was then fitted, including all predictor
variables regardless whether or not they were statistically
associated with a CV event in univariate analysis. Having
fitted the full multivariate model, a backward selection
process was used to exclude variables that did not improve
model fit. Likelihood ratio tests were used to compare
model fit. The results of complete case analyses can be
biased because the cumulative effect of missing data in
several variables often leads to exclusion of a substantial
proportion of the original sample, causing a loss of preci-
sion and power (23). This bias can be overcome by using
multiple imputation methods, which we did using the
Imputation by Chained Equations procedure in Stata (23–
26). For logistic regression, 10 times as many outcome
events as predictor variables are required to avoid model
over fit. Using clinical judgment, we initially created a
model using traditional risk factors (age, sex, BMI, smok-
ing status, hypertension, and diabetes mellitus), and
then a model with only disease-specific items (BVAS, pro-
teinase 3 [PR3] and myeloperoxidase [MPO] antineutro-
phil cytoplasmic antibody [ANCA] status, baseline esti-
mated glomerular filtration rate [GFR], age, and sex).
Regression diagnostics were performed to identify outly-
ing data that may overly influence the model. Cholesterol
measurements were not recorded at baseline, and therefore
could not be included in the traditional risk factor model.
Performance of the predictive model was assessed in
terms of calibration and discrimination. Calibration mea-




(n  180) P†
Age, mean  SD years 58  14 47  16  0.001
Male sex 288 (54) 108 (60) 0.17
WG 281 (53) 180 (100)  0.001
Microscopic polyangiitis 254 (47) 0 (0)  0.001
New diagnosis of vasculitis 535 (100) 80 (44)  0.001
Existing diagnoses of vasculitis 0 (0) 100 (56)  0.001
Serum creatinine, mean  SD moles/liter 341  321 153  177  0.001
BVAS2 (new/worse) score, mean  SD 16.9  9.2 NA –
BVAS/WG score, mean  SD NA 6.9  3.4 –
MPO ANCA positive 190 (35.5) 21 (12)  0.001
PR3 ANCA positive 302 (56.5) 131 (73)  0.001
ESR, mean  SD mm/hour 76  36 NA –
CRP level, mean  SD mg/liter 88  139 NA –
* Values are the number (percentage) unless otherwise indicated. EUVAS  European Vasculitis Study Group;
WGET  Wegener’s Granulomatosis Etanercept Trial; WG  Wegener’s granulomatosis; BVAS2  Birmingham
Vasculitis Activity Score, version 2; NA  not available; MPO  myeloperoxidase; ANCA  antineutrophil
cytoplasmic antibody; PR3  proteinase 3; ESR  erythrocyte sedimentation rate; CRP  C-reactive protein.
† Calculated using chi-square test of association for categorical variables and 2-sample t-test for continuous
variables.
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sures how closely predicted risk agrees with the observed
risk. This was assessed for each tenth of predicted risk
ensuring 10 equally sized groups, and a Hosmer-Leme-
show goodness-of-fit test was performed (27). Discrimina-
tion is the ability of the model to differentiate between
patients who experienced a CV event during the 5 years
of followup in this study and those who did not. We
tested discrimination by calculating the area under the
receiver operating characteristic (AUROC) curve 1) in
the original data set, 2) by bootstrapping, and 3) by
testing in the WGET cohort (18). To assess the goodness
of fit of a logistic model, we used McKelvey-Zavoina
pseudo R2 (28,29).
In addition, classification and regression tree (CART)
analysis, a binary recursive partitioning method, was per-
formed in the R statistical software package (R Founda-
tion) using the “party” package. In each node of the tree, a
significance test was made between any of the covariates
and the response, and a split was established when the P
value was 0.05.
RESULTS
A total of 535 patients (281 with WG, 254 with MPA),
including patients who died, had 5 years of followup; 74
Table 2. Baseline variables for patients included in the development of the CV risk prediction
model (n  427)*
Total no. of
patients
No. (%) of patients




crude OR (95% CI) P
Trial name
CYCAZAREM 131 14 (10.7) 1.00
CYCLOPS 107 14 (13.1) 1.26 (0.57–2.77) 0.57
MEPEX 99 18 (18.2) 1.86 (0.87–3.95) 0.11
NORAM 90 4 (4.4) 0.39 (0.12–1.22) 0.11
Diagnosis
MPA 190 31 (16.3) 1.00
WG 237 19 (8.0) 0.45 (0.24–0.82) 0.009
PR3 ANCA
No 168 33 (19.6) 1.00
Yes 257 17 (6.6) 0.29 (0.16–0.54)  0.001
MPO ANCA
No 279 22 (7.9) 1.00
Yes 146 28 (19.2) 2.78 (1.52–5.06) 0.001
Age 1.58 (1.22–2.06) 0.001
Sex
Female 207 23 (11.1) 1.00
Male 220 27 (12.3) 1.12 (0.62–2.02) 0.71
BMI 1.03 (0.93–1.14) 0.57
Ever smoked
No 160 15 (9.4) 0.61 (0.32–1.18) 0.14
Yes 132 20 (15.2) 1.00
Diabetes mellitus
No 339 40 (11.8) 1.00
Yes 14 3 (21.4) 2.06 (0.57–7.40) 0.27
New hypertension
No 350 33 (9.4) 1.00
Yes 72 16 (22.2) 2.74 (1.41–5.30) 0.003
Hemoglobin 426 0.86 (0.75–1.00) 0.051
Log WBC† 427 1.20 (0.56–2.59) 0.63
Platelets‡ 427 0.97 (0.95–0.99) 0.011
Estimated GFR (MDRD) 426 0.83 (0.74–0.93) 0.001
BVAS score 422 1.02 (0.99–1.05) 0.23
VDI 6-month score 238 1.38 (1.09–1.74) 0.007
* CV  cardiovascular; OR  odds ratio; 95% CI  95% confidence interval; CYCAZAREM  maintenance therapy with
azathioprine vs. cyclophosphamide in patients with a renal manifestation or with generalized life-threatening disease; CY-
CLOPS  induction therapy comparing daily oral cyclophosphamide with pulsed intravenous cyclophosphamide in patients
with generalized disease; MEPEX  comparison of plasma exchange to methyl prednisone in patients with severe renal disease;
NORAM  comparison of methotrexate to cyclophosphamide for induction treatment in patients with creatinine 150
mmoles/liter and without critical organ-threatening disease; MPA  microscopic polyangiitis; WG  Wegener’s granulomatosis;
PR3  proteinase 3; ANCA  antineutrophil cytoplasmic antibody; MPO  myeloperoxidase; BMI  body mass index; WBC 
white blood cell; GFR  glomerular filtration rate; MDRD  Modification of Diet in Renal Disease study equation; BVAS 
Birmingham Vasculitis Activity Score (new/worse); VDI  Vasculitis Damage Index.
† A log transformation was performed on the WBC count to achieve a normal distribution.
‡ For a 10-unit increase in platelet count.
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(13.8%) of 535 patients had at least 1 CV event: 33 (11.7%)
of 281 WG versus 41 (16.1%) of 254 MPA. There were 32
(6.0%) CV deaths, 25 (4.7%) nonfatal strokes, and 42
(7.9%) had a nonfatal MI, coronary artery bypass graft, or
percutaneous coronary intervention. The observed age-
standardized CV death rate for the EUVAS cohort was 699
compared to the predicted rate of 190 per 100,000 popu-
lation per year.
When developing the predictive model, 31 patients were
excluded due to missing baseline values, 32 due to missing
outcome records, and 45 due to CV disease prior to trial
entry. The remaining 427 patients, 50 with a CV event (19
of 237 WG versus 31 of 190 MPA; P  0.01), were used to
develop the model. A summary of the baseline variables
analyzed for the 427 patients is provided in Table 2. Smok-
ing status was available in 292 of 427 patients in the study:
7.3% were current smokers, 23.7% were ex-smokers, and
37.5% had never smoked. For analysis, we combined the
current and ex-smokers as an ever smoked group. Compar-
ing those that had never smoked to ever smoked gave an
Figure 1. Final model to predict the risk of a cardiovascular (CV)
event in the first 5 years from diagnosis with microscopic poly-
angiitis or Wegener’s granulomatosis. The 5-year CV risk is shown
as: green  low risk (10%), orange  moderate risk (10–20%),
and red  high risk (20%). HTN  hypertension, defined as
diastolic blood pressure 95 mm Hg at the time of diagnosis
(score 1 if present, 0 if absent); PR3  proteinase 3; ANCA 
antineutrophil cytoplasmic antibody; PR3 ANCA  1 if present, 0
if absent.
Figure 2. Receiver operating characteristic (ROC) curves compar-
ing our new disease-specific model with the traditional points-
based Cox Framingham model. EUVAS  European Vasculitis
Study Group; WGET  Wegener’s Granulomatosis Etanercept
Trial.















Age (n  427)† 1.58 (1.22–2.06) 1.58 (1.22–2.06) 11.7 1.35 (1.02–1.79) 1.45 (1.11–1.90)
Sex (n  427)
Female 1.00 1.00 1.00 –
Male 1.12 (0.62–2.02) 1.12 (0.62–2.02) 0.1 1.10 (0.56–2.15) –
BMI (n  196) 1.03 (0.93–1.14) 1.03 (0.93–1.14) 1.3 – –
BVAS1 (n  422) 1.02 (0.99–1.05) 1.02 (0.99–1.05) 1.0 – –
Estimated GFR (n  426)† 0.83 (0.74–0.93) 0.83 (0.74–0.93) 11.3 0.93 (0.82–1.06) –
ANCA MPO (n  425)
No 1.00 1.00 – –
Yes 2.77 (1.52–5.05) 2.78 (1.52–5.06) 6.7 – –
ANCA PR3 (n  425)
No 1.00 1.00 1.00 1.00
Yes 0.29 (0.16–0.54) 0.29 (0.16–0.54) 10.0 0.41 (0.21–0.80) 0.39 (0.20–0.74)
Ever smoked (n  427)
Yes 1.00 1.00 1.00 –
No 0.58 (0.28–1.18) 0.61 (0.32–1.18) 2.3 0.62 (0.29–1.31) –
New hypertension (n  422)
No 1.00 1.00 1.00 1.00
Yes 2.74 (1.42–5.32) 2.74 (1.41–5.30) 4.0 1.92 (0.93–3.95) 1.97 (0.98–3.95)
Previous diabetes mellitus
(n  353)
No 1.00 1.00 – –
Yes 2.04 (0.55–7.62) 2.06 (0.57–7.40) 0.9 – –
* OR  odds ratio; 95% CI  95% confidence interval; BMI  body mass index; BVAS1  Birmingham Vasculitis Activity Score, version 1; GFR 
glomerular filtration rate; ANCA  antineutrophil cytoplasmic antibody; MPO  myeloperoxidase; PR3  proteinase 3.
† For a 10-unit increase.
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odds ratio (OR) of 0.61 (95% confidence interval [95%
CI] 0.32–1.18, P  0.14) for any CV event within 5 years.
Reanalyzing the data comparing never smoked to cur-
rent smokers gave an OR of 0.90 (95% CI 0.24 –3.36, P 
0.87).
All of the traditional and disease-specific risk factors
were considered for inclusion in the final model (Table 3).
To avoid overfitting, we considered the effect of each pre-
dictor independently and assessed the effect of confound-
ing for that predictor with each risk factor. Variables that
were significantly associated with CV events in univariate
analysis or were important confounders were included in
the full multivariable regression model. Older age was
associated with an increased risk of a CV event; however,
the effect was slightly attenuated due to confounding by
the estimated GFR. Crude analyses suggested that an in-
creasing estimated GFR was associated with a reduced CV
risk, but this was attenuated after adjustment for age and
PR3 ANCA. Because MPO ANCA and PR3 ANCA were
strongly inversely associated with each other, only PR3
ANCA was considered for inclusion in the full model
because it was a statistically stronger predictor. PR3 ANCA
was associated with a reduced CV risk and MPO ANCA
with an increased CV risk. In both cases this was attenu-
ated slightly after adjusting for age, estimated GFR, and
diastolic hypertension. Patients with diastolic hyperten-
sion were at an increased risk of CV events. This effect was
attenuated after adjusting for age, estimated GFR, and PR3
ANCA, but strengthened if adjusting for sex and smoking
status. Sex, BMI, smoking status, baseline BVAS score, and
diabetes mellitus were not associated with CV events.
Age, sex, estimated GFR, PR3 ANCA status, smoking
status, and diastolic hypertension at baseline were in-
cluded in creating the full multivariable regression model.
After backward selection, age, PR3 ANCA status, and dia-
stolic hypertension remained in the final model. The final
model is shown in Figure 1. Cutoffs of 10% as low risk,
10–20% as moderate risk, and 20% as high risk were
chosen to provide memorable categories. In the EUVAS
cohort, 245 patients (57.4%) fell into the low-risk group,
106 (24.8%) fell into the moderate-risk group, and 76
(17.8%) fell into the high-risk group using our new 5-year
risk prediction model. Observed CV events consisted of 15
(6.1%) of 245 for the low-risk group, 14 (13.2%) of 106 for
the medium-risk group, and 21 (27.6%) of 76 for the high-
risk group.
The Hosmer-Lemeshow goodness-of-fit test suggested
that the model was well calibrated (P  0.55). The model
demonstrated good discrimination, with an AUROC of
0.73 for the original data set, bootstrapped analysis gave a
bias-corrected AUROC of 0.72, and validation with the
WGET cohort demonstrated very good discrimination,
with an AUROC of 0.80 (Figure 2). The pseudo R2 (Mc-
Kelvey-Zavoina) for the final model was 18.5%. The model
was better at predicting coronary events than strokes: an
AUROC of 0.85 (95% CI 0.77–0.92) with a pseudo R2 of
49.7% versus an AUROC of 0.70 (95% CI 0.60–0.80) and
a pseudo R2 of 19.6% for the EUVAS cohort. In compari-
son, the AUROC for any cardiac event using the points-
based Cox Framingham model was 0.65 (95% CI 0.57–
0.72) (Figure 2).
Figure 3 shows the conditional inference trees we cre-
ated using CART analysis to predict CV events. In this tree,
PR3 ANCA status was the most discriminative starting
point. Thereafter, age, estimated GFR, and BVAS items
were important predictors of the risk of a CV event. Using
this inference tree, a patient that was PR3 ANCA positive,
had an estimated GFR of 32.3 ml/minute, and no items
present on the CV section of the BVAS had the lowest risk
(1.4%) of a CV event in the following 5 years. In the
EUVAS cohort, 146 individuals fit these criteria and 2
(1.4%) of them had a CV event. Conversely, 12 (44%) of 27
patients that were PR3 ANCA negative and age 72.4
years had a CV event.
DISCUSSION
Within 5 years of diagnosis of WG or MPA, approximately
14% of patients will have a major CV event. The age-
standardized annual CV mortality rate of 699 per 100,000
in this cohort is 3.7 (95% CI 3.2–4.3) times higher than we
would expect in the background population. The result of
our study adds further weight to the growing body of
evidence that individuals with a diagnosis of WG or MPA
are at a significantly increased risk of CV morbidity and
mortality (10,11).
There are many potential reasons for the increased CV
risk. Endothelial dysfunction, which is a recognized risk
factor for CV disease (16,30–32), has been shown to be
present in ANCA-associated vasculitis and is independent
of disease activity or renal involvement (33). Renal dys-
function, which occurs frequently in patients with MPA
and WG, is an established contributor to CV disease by
affecting metabolic, inflammatory, and hemodynamic
pathways (34). In addition, vasculitis represents a chronic
inflammatory state, and other inflammatory diseases, such
as rheumatoid arthritis and systemic lupus erythematosus,
have strong associations with CV disease (35,36). Animal
Figure 3. Conditional inference tree showing an approximate risk
of a cardiovascular event within 5 years based on baseline clinical
features. The percentage shown is the risk of a cardiovascular
event within 5 years of diagnosis of Wegener’s granulomatosis or
microscopic polyangiitis. N  cardiovascular events/number of
individuals in group; PR3  proteinase 3; ANCA  antineutrophil
cytoplasmic antibody; eGFR  estimated glomerular filtration
rate; MDRD  Modification of Diet in Renal Disease; BVAS 
Birmingham Vasculitis Activity Score.
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models suggest that vessels following arteritis are more
prone to atherosclerotic change (37). Furthermore, cortico-
steroids, which are a routine part of treatment for vasculi-
tis, present an interesting conflict: they increase CV risk by
accelerating the development of diabetes mellitus (38),
dyslipidemia (39), and hypertension (40), but may also
have a protective role in vasculitis by reducing systemic
inflammation and improving endothelial dysfunction
(13,15,41).
We have developed 2 complementary models (logistic
regression and CART) to predict the 5-year CV risk at the
time of the first presentation with WG and MPA. The
regression model was validated in the WGET cohort and
performed better than existing generic risk tools available
for the general population. Both models identified a posi-
tive PR3 ANCA status as an important determinant of
lower risk among those with vasculitis. However, almost
all of the patients in the EUVAS trials were either MPO or
PR3 ANCA positive, implying that those with a positive
MPO ANCA are associated with an increased risk of CV
disease. Interestingly, neither model identified sex as a
predictor of risk, suggesting that vasculitis may remove the
CV risk benefit usually observed in women. A potential
explanation for this is that a large proportion of the women
enrolled in the EUVAS trials were in the peri- or post-
menopausal age group (mean  SD age 58  14 years, i.e.,
84% were age 46 years at baseline), and others may have
been pushed into premature menopause by the use of
cyclophosphamide. In the regression model, a positive
PR3 ANCA status decreased the risk of a CV event, and
older age and the presence of diastolic hypertension at the
time of enrollment into the study increased the risk. The
discrimination of this model compares very favorably with
the QRISK score (AUROC curve of 0.76 for men and 0.79
for women) and the 1991 Framingham equation (AUROC
curve of 0.74 for men and 0.76 for women) (42–44). Our
second model used CART analysis to create an inference
tree to determine the CV risk, which provides insight into
possible interactions between variables. For example, the
inference tree shows that patients who are PR3 ANCA
positive and have good renal function are generally at low
risk for CV events; however, if these patients have any CV
system involvement at baseline then their risk of a major
CV event is 9-fold higher.
The main reason for developing risk algorithms is not
just prognostication, but prognostication that allows clini-
cians to develop and test preventative strategies. For vas-
culitis, we do not yet know whether treating traditional
risk factors such as smoking and dyslipidemia would
change the CV outcome or whether it is more important to
treat the inflammation and renal disease. Our model could
be used to do the power calculation to determine how
many patients would be needed in an interventional study
to detect a 20% reduction in CV events. For example, you
would need X, high-risk patients versus Y, low-risk pa-
tients or Z, all patients.
There are limitations to our study. Lipid results, glyco-
sylated hemoglobin levels, and specific CV medications
associated with the prevention of CV disease (e.g., aspirin,
statins, angiotensin-converting enzyme inhibitors) were
absent from the baseline data set, which may have omitted
important predictor variables. The original EUVAS trials
were not designed to evaluate CV risk and therefore, a
study designed to look specifically at this issue may have
resulted in an even stronger model. This is something to
aspire to for future studies. However, ours is the only
disease-specific model currently available for vasculitis.
When interpreting our statistical model, it is important to
remember that we are trying to predict a specific outcome
and the key objective is to predict the risk accurately.
There are potentially a large number of variables that have
overlapping contributions to the CV risk, but if a few
variables are able to predict the risk with the same accu-
racy, then whether or not we include the other variables in
the equation should not matter. For example, “hyperten-
sion” in our model would very likely have an overlapping
contribution to CV risk with renal impairment. The pa-
tients included in our development data set comprised a
larger proportion of patients with mild WG (NORAM trial)
and more patients with severe MPA (MEPEX trial); there-
fore, patient selection bias may have unduly influenced
the CV outcomes despite our best efforts to correct for
renal function and disease severity in our statistical mod-
eling. In addition, there are some major differences be-
tween the development and validation groups; all of the
patients had newly diagnosed WG or MPA in the EUVAS
trials, whereas the WGET cohort only included WG but
comprised patients with new and existing disease. We
acknowledge that a large mixed cohort with both WG and
MPA patients would have been the best cohort for testing
and validation. However, there are currently no other suit-
able cohorts available (i.e., with sufficient number of pa-
tients, a long enough duration of followup, and accurate
recording of CV events). Therefore, we have used the best
alternative possible. There was only 1 stroke in the WGET
cohort, so validation of this outcome needs to be inter-
preted with caution. Despite these potential biases and
cohort differences, our model still works very well in both
groups, confirming the strength of our model and reinforc-
ing that age, diastolic hypertension, and PR3 ANCA status
are strong predictors of CV outcomes in patients with
ANCA-associated vasculitis. A further consideration is
that renal function may change dramatically from baseline
to later in the disease; therefore, its use as a predictive
variable may depend on when it is measured. The effect of
disease flares, cumulative dose of steroids, and changes in
renal function will need to be taken into account when
evaluating CV risk at different time points in the disease
course.
In conclusion, we have shown that the risk of a CV event
in the first 5 years after the diagnosis of WG or MPA is
raised. To quantify this risk for an individual patient, we
have created and validated a statistical model using base-
line clinical features. Identifying those at highest risk may
help target those who require closer monitoring and fur-
ther intervention.
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